Altogether, these results suggest that the evaluation of co-expression of DLL3 and PDL1 antigens may potentially be used for predicting sensitivity of SCLC to treatment and overall survival in SCLC patients. The gene discussed is CD274; the disease is small cell lung carcinoma.